For many of us, when we think of microbiomes, our first thoughts are probably about the beneficial microorganisms that live in our guts.
Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region – Biotech Investments
EQS-News: Formycon AG / Key word(s): Agreement Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region 05.02.2025